Sampo plc, stock exchange release, 9 December 2025 at 8:30 am EET Sampo plc’s share buybacks 8 December 2025 On 8 December 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  5,416 9.96 AQEU    105,692 9.96 CEUX  23,845 9.96 TQEX  126,805 9.96 XHELTOTAL 261,758 9.96  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November 2025,...

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value CreationCompletion of Tedopi’s phase 3 in Non-Small Cell Lung Cancer One or two new rare/specialty indications for Lusvertikimab Subcutaneous formulation and combination strategies for Lusvertikimab in UC Management webcast on Wednesday, December 10th at 6pm CETNantes, France, December 9, 2025 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its new three-year strategic plan designed to accelerate development of its most promising programs while maintaining financial discipline. This plan creates multiple near-term catalysts and reinforces OSE Immunotherapeutics’ commitment to immunology innovation. Four Value Creating OpportunitiesComplete Tedopi’s Artemia Phase 3 Trial at Limited Cost: The...

Renault Group and Ford form a strategic partnership for passenger and commercial vehicles, starting with two affordable electric cars in EuropeThe companies have signed a partnership agreement to develop two Ford-branded passenger electric vehicles based on Renault Group’s Ampere platform. Additionally, the companies will explore the opportunity to collaborate in the commercial vehicle segment in Europe, to jointly develop and manufacture Renault and Ford-branded selected light commercial vehicles. The partnership combines the expertise and industrial scale of Renault Group and Ford in Europe and will enhance the competitiveness of both parties.Paris, France and Cologne, Germany – December 9, 2025 Renault Group and Ford today announced a landmark strategic partnership aimed at expanding Ford’s electric vehicles offering to European...

Picture David HaleNew CEO of Ascom Holding AGAd hoc announcement pursuant to Art. 53 LRBaar, Switzerland, December 9, 2025 David Hale, an executive leader with a proven track record and over two decades of technology and industrial expertise, has been appointed by the Board of Directors of Ascom Holding AG as the new CEO of the Ascom Group. David Hale will join Ascom on February 4, 2026. Michael Reitermann will step down as interim CEO at that time and remain an ordinary member of the Board of Directors. David Hale has more than 25 years of international leadership experience in the medical device and pharmaceutical industries, including five years as CEO of the Guerbet Group, headquartered in France. Previously, David Hale held senior positions at General Electric (GE), including at GE Healthcare Digital in the US and GE Healthcare...

The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. The test will help improve diagnostic accuracy for millions of women1 affected by vaginitis annually, delivering more accurate and specific results. This test offers faster diagnosis by using a single vaginal swab for broader sexual health testing, eliminating the need for an additional sample.Basel, 9 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collected using the cobas PCR Media proprietary tube. Clinicians typically rely...

London, United Kingdom, Dec. 08, 2025 (GLOBE NEWSWIRE) — Daedalus Special Acquisition Corp. (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Co-Chief Executive Officers Husnu Akin Babayigit and Orkun Kilic, today announced the upsized pricing of its initial public offering of 22,500,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-fourth of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share. The units are expected to trade on the Global Market tier of the Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “DSACU” beginning December 9, 2025. No fractional warrants will be issued upon separation of the...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or the “Company”) (TSX: RIO; OTCQX: RIOFF; BVL: RIO) is pleased to announce that due to strong investor demand, the Company, Raymond James Ltd., (“Raymond James”), Stifel Nicolaus Canada Inc. (“Stifel”), and BMO Nesbitt Burns Inc. (“BMO”), the co-lead underwriters and joint bookrunners (collectively, the “Underwriters”) have upsized the previously announced “bought deal” financing from C$140 million to approximately C$166 million, or approximately US$120 million (the “Equity Financing”). Under the Equity Financing, the Underwriters have agreed to purchase, on a “bought deal” basis, 74,865,000 Subscription Receipts of the Company (“Subscription...

BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies of its novel BCL2 inhibitor, Mesutoclax (ICP-248), were presented at the 67th Annual Meeting of the American Society of Hematology (ASH). Mesutoclax demonstrated remarkable efficacy and a favorable safety profile in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and acute myeloid leukemia (AML). The study of mesutoclax in the treatment of relapsed/refractory MCL was selected for oral presentation, while the CLL/SLL and AML studies were chosen for poster presentations. Oral Presentation Title: Efficacy and tolerability of mesutoclax...

BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) — Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, announced today the grant of an inducement restricted stock award of 1,000,000 shares of common stock (“Restricted Stock Award”) to a new employee under the Netcapital Inc. 2023 Omnibus Equity Incentive Plan (the “Plan”). The Restricted Stock Award was granted as an inducement under the Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Equity Incentive Plan provides for the issuance of equity awards in the form of inducement grants pursuant to Nasdaq Listing Rule 5635(c). The Restricted Stock Award will have voting rights upon issuance and will vest, in whole or in part, on March 15, 2027, with the number of shares of...

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy  Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles Strong efficacy data support potential advancement to earlier treatment lines for a broader patient populationROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the latest data on Olverembatinib, the Company’s novel drug, in second-line treatment of patients with chronic myeloid leukemia...